Regeneron Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Regeneron Pharmaceuticals is Leonard Schleifer, benoemd in Jan1988, heeft een ambtstermijn van 36.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.18M, bestaande uit 22.9% salaris en 77.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.23% van de aandelen van het bedrijf, ter waarde € 1.68B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 17.9 jaar.

Belangrijke informatie

Leonard Schleifer

Algemeen directeur

US$8.2m

Totale compensatie

Percentage CEO-salaris	22.9%
Dienstverband CEO	36.8yrs
Eigendom CEO	2.2%
Management gemiddelde ambtstermijn	7.2yrs
Gemiddelde ambtstermijn bestuur	17.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Leonard Schleifer's beloning veranderd ten opzichte van Regeneron Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$4b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

Compensatie versus markt: De totale vergoeding ($USD 8.18M ) Leonard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.87M ).

Compensatie versus inkomsten: De vergoeding van Leonard is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Leonard Schleifer (71 yo)

36.8yrs

Tenure

US$8,184,338

Compensatie

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Leonard Schleifer	Co-Founder	36.8yrs	US$8.18m	2.23% € 1.7b
George Yancopoulos	Co-Founder	23.8yrs	US$7.76m	1.07% € 811.4m
Andrew Murphy	Executive Vice President of Research	5.8yrs	US$8.43m	0.048% € 36.2m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16.6yrs	US$8.76m	0.031% € 23.8m
Christopher Fenimore	Senior VP of Finance & CFO	less than a year	geen gegevens	0.017% € 13.2m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.8yrs	geen gegevens	geen gegevens
Bob McCowan	Senior VP of IT & Chief Information Officer	3.8yrs	geen gegevens	geen gegevens
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	geen gegevens	geen gegevens
Joseph LaRosa	Executive VP	13.2yrs	US$7.13m	0.036% € 26.9m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.8yrs	geen gegevens	geen gegevens
Christina Chan	Senior Vice President of Corporate Affairs	no data	geen gegevens	geen gegevens
Sally Paull	Executive Vice President of Human Resources	8.6yrs	geen gegevens	geen gegevens

7.2yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RGO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Leonard Schleifer	Co-Founder	36.8yrs	US$8.18m	2.23% € 1.7b
George Yancopoulos	Co-Founder	23.8yrs	US$7.76m	1.07% € 811.4m
Christine Poon	Lead Independent Director	14yrs	US$748.01k	0.00073% € 552.4k
Arthur Ryan	Independent Director	21.8yrs	US$724.99k	0.016% € 12.4m
Michael Brown	Independent Director	33.4yrs	US$728.99k	0.012% € 8.8m
Joseph Goldstein	Independent Director	33.4yrs	US$709.99k	0.0046% € 3.5m
George Sing	Independent Director	36.8yrs	US$724.99k	0.026% € 20.0m
N. Coles	Independent Director	7.8yrs	US$704.99k	0.000010% € 7.6k
Craig Thompson	Independent Director	2.1yrs	US$247.79k	0% € 0
Huda Zoghbi	Independent Director	8.2yrs	US$714.99k	0% € 0
Bonnie Bassler	Independent Director	8.2yrs	US$709.99k	0.0013% € 968.5k
Kathryn Guarini	Independent Director	1.2yrs	US$1.03m	0% € 0

17.9yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RGO zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.9 jaar).

Regeneron Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Senior VP of Finance & CFO recently sold €5.7m worth of stock

Insider recently sold €5.2m worth of stock

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Insider recently sold €7.1m worth of stock

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Senior VP of Finance & CFO recently sold €5.7m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Insider recently sold €5.2m worth of stock

Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold €7.1m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd